| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Endocarditis | 6 | 2019 | 368 | 3.00 | Why? |
| Endocarditis, Bacterial | 8 | 2019 | 344 | 2.99 | Why? |
| Heart Valve Prosthesis Implantation | 4 | 2019 | 552 | 1.57 | Why? |
| Denmark | 20 | 2022 | 2654 | 1.23 | Why? |
| Oxygen Consumption | 2 | 2021 | 711 | 1.20 | Why? |
| Heart Valve Diseases | 2 | 2019 | 355 | 1.07 | Why? |
| Cerebrovascular Circulation | 4 | 2020 | 340 | 0.93 | Why? |
| Indoleacetic Acids | 1 | 2019 | 13 | 0.83 | Why? |
| Bicycling | 2 | 2018 | 133 | 0.81 | Why? |
| Arabidopsis Proteins | 1 | 2019 | 54 | 0.80 | Why? |
| Oxygen | 4 | 2021 | 3715 | 0.80 | Why? |
| Models, Cardiovascular | 1 | 2020 | 153 | 0.79 | Why? |
| Drosophila Proteins | 1 | 2019 | 67 | 0.78 | Why? |
| Arabidopsis | 1 | 2019 | 88 | 0.77 | Why? |
| Homeodomain Proteins | 1 | 2019 | 93 | 0.77 | Why? |
| Capillaries | 1 | 2020 | 257 | 0.71 | Why? |
| Germ Cells, Plant | 1 | 2017 | 1 | 0.70 | Why? |
| Seed Dispersal | 1 | 2017 | 2 | 0.70 | Why? |
| Depsipeptides | 4 | 2018 | 61 | 0.69 | Why? |
| Insulin, Long-Acting | 1 | 2017 | 30 | 0.68 | Why? |
| Liraglutide | 1 | 2017 | 47 | 0.66 | Why? |
| Microcirculation | 2 | 2020 | 447 | 0.66 | Why? |
| Aortic Valve Insufficiency | 1 | 2018 | 136 | 0.65 | Why? |
| Heart Valve Prosthesis | 2 | 2019 | 533 | 0.64 | Why? |
| Microvessels | 1 | 2021 | 490 | 0.63 | Why? |
| Streptococcal Infections | 1 | 2019 | 255 | 0.62 | Why? |
| Echocardiography, Transesophageal | 1 | 2019 | 447 | 0.60 | Why? |
| Prosthesis-Related Infections | 1 | 2019 | 302 | 0.60 | Why? |
| Staphylococcal Infections | 3 | 2019 | 1099 | 0.59 | Why? |
| Defibrillators, Implantable | 2 | 2019 | 624 | 0.57 | Why? |
| Fruit | 1 | 2017 | 313 | 0.56 | Why? |
| Pacemaker, Artificial | 1 | 2018 | 431 | 0.52 | Why? |
| Bacteremia | 2 | 2019 | 1372 | 0.46 | Why? |
| Aortic Valve Stenosis | 1 | 2018 | 741 | 0.41 | Why? |
| Flowers | 2 | 2019 | 31 | 0.38 | Why? |
| Heart Defects, Congenital | 1 | 2018 | 933 | 0.36 | Why? |
| Gene Expression Regulation, Plant | 2 | 2019 | 110 | 0.36 | Why? |
| Blood Flow Velocity | 2 | 2020 | 193 | 0.35 | Why? |
| Virus Latency | 3 | 2018 | 251 | 0.34 | Why? |
| Follow-Up Studies | 11 | 2021 | 17020 | 0.32 | Why? |
| Acute Coronary Syndrome | 1 | 2020 | 2107 | 0.32 | Why? |
| Stroke | 6 | 2021 | 8839 | 0.31 | Why? |
| Diabetes Complications | 1 | 2018 | 2358 | 0.31 | Why? |
| Toll-Like Receptor 9 | 2 | 2017 | 72 | 0.28 | Why? |
| Anti-Retroviral Agents | 3 | 2018 | 1099 | 0.28 | Why? |
| Mortality | 2 | 2018 | 7132 | 0.28 | Why? |
| Vasoconstrictor Agents | 2 | 2020 | 714 | 0.28 | Why? |
| Antiretroviral Therapy, Highly Active | 3 | 2018 | 952 | 0.27 | Why? |
| Candidemia | 2 | 2019 | 353 | 0.27 | Why? |
| Hypoglycemic Agents | 1 | 2017 | 2165 | 0.27 | Why? |
| Staphylococcus aureus | 3 | 2019 | 844 | 0.27 | Why? |
| Registries | 7 | 2020 | 12327 | 0.26 | Why? |
| HIV-1 | 5 | 2018 | 3365 | 0.25 | Why? |
| AIDS Vaccines | 2 | 2018 | 452 | 0.25 | Why? |
| Forecasting | 1 | 2017 | 4492 | 0.24 | Why? |
| Computer Simulation | 1 | 2017 | 4982 | 0.24 | Why? |
| Incidence | 11 | 2021 | 25622 | 0.24 | Why? |
| Cardiology | 1 | 2017 | 2873 | 0.23 | Why? |
| Diffusion | 1 | 2020 | 73 | 0.22 | Why? |
| Societies, Medical | 1 | 2017 | 6907 | 0.21 | Why? |
| Coagulase | 1 | 2019 | 44 | 0.20 | Why? |
| Regional Blood Flow | 1 | 2020 | 172 | 0.20 | Why? |
| Response Elements | 1 | 2019 | 54 | 0.20 | Why? |
| Postoperative Complications | 1 | 2018 | 5861 | 0.20 | Why? |
| Viremia | 2 | 2017 | 1020 | 0.20 | Why? |
| Poisson Distribution | 1 | 2020 | 348 | 0.20 | Why? |
| Enterococcus faecalis | 1 | 2019 | 126 | 0.19 | Why? |
| Neisseria meningitidis, Serogroup B | 1 | 2019 | 66 | 0.19 | Why? |
| Phenylephrine | 1 | 2017 | 20 | 0.18 | Why? |
| B-Lymphocytes, Regulatory | 1 | 2018 | 24 | 0.18 | Why? |
| Ibuprofen | 1 | 2020 | 156 | 0.18 | Why? |
| Ephedrine | 1 | 2017 | 24 | 0.18 | Why? |
| Collateral Circulation | 1 | 2018 | 56 | 0.18 | Why? |
| Diffusion Magnetic Resonance Imaging | 2 | 2018 | 317 | 0.18 | Why? |
| HIV Infections | 7 | 2018 | 11620 | 0.18 | Why? |
| Hepatitis A Vaccines | 1 | 2018 | 52 | 0.18 | Why? |
| Confidence Intervals | 1 | 2020 | 744 | 0.18 | Why? |
| Middle Aged | 27 | 2021 | 270681 | 0.17 | Why? |
| Plant Cells | 1 | 2017 | 11 | 0.17 | Why? |
| Proportional Hazards Models | 3 | 2020 | 6543 | 0.17 | Why? |
| Administration, Intravenous | 2 | 2019 | 1115 | 0.17 | Why? |
| Anisotropy | 1 | 2017 | 56 | 0.17 | Why? |
| Meningitis, Meningococcal | 1 | 2019 | 114 | 0.17 | Why? |
| Female | 34 | 2021 | 380317 | 0.17 | Why? |
| Male | 32 | 2021 | 367725 | 0.17 | Why? |
| Hepatitis B Antibodies | 1 | 2018 | 142 | 0.17 | Why? |
| Meningitis, Cryptococcal | 1 | 2018 | 79 | 0.17 | Why? |
| Blood Culture | 1 | 2019 | 308 | 0.17 | Why? |
| Antigens, Fungal | 1 | 2018 | 106 | 0.16 | Why? |
| Magnetic Resonance Angiography | 1 | 2018 | 282 | 0.16 | Why? |
| Aged | 18 | 2021 | 215776 | 0.16 | Why? |
| Cardiomyopathy, Hypertrophic | 1 | 2019 | 193 | 0.16 | Why? |
| Anti-Bacterial Agents | 4 | 2019 | 10083 | 0.16 | Why? |
| Reverse Transcriptase Inhibitors | 1 | 2018 | 309 | 0.16 | Why? |
| Leisure Activities | 1 | 2018 | 221 | 0.16 | Why? |
| Reoperation | 1 | 2019 | 544 | 0.16 | Why? |
| Quarantine | 2 | 2021 | 18418 | 0.16 | Why? |
| Antibiotics, Antineoplastic | 1 | 2017 | 128 | 0.16 | Why? |
| Diabetes Mellitus | 1 | 2018 | 8207 | 0.15 | Why? |
| Ischemic Attack, Transient | 1 | 2020 | 439 | 0.15 | Why? |
| Meningococcal Vaccines | 1 | 2019 | 225 | 0.15 | Why? |
| Prosthesis Implantation | 1 | 2018 | 261 | 0.15 | Why? |
| Hepatitis B Vaccines | 1 | 2018 | 245 | 0.15 | Why? |
| Glucagon-Like Peptide-1 Receptor | 1 | 2017 | 138 | 0.15 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2017 | 6166 | 0.15 | Why? |
| Promoter Regions, Genetic | 1 | 2019 | 823 | 0.15 | Why? |
| Risk Factors | 10 | 2021 | 71621 | 0.15 | Why? |
| Humans | 49 | 2022 | 930598 | 0.15 | Why? |
| Pneumonia, Mycoplasma | 1 | 2018 | 292 | 0.15 | Why? |
| Mitral Valve | 1 | 2019 | 342 | 0.15 | Why? |
| HIV Seropositivity | 1 | 2017 | 320 | 0.14 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 2018 | 260 | 0.14 | Why? |
| HIV Protease Inhibitors | 1 | 2018 | 434 | 0.14 | Why? |
| Macrolides | 1 | 2018 | 369 | 0.14 | Why? |
| Magnetic Resonance Imaging | 4 | 2017 | 6551 | 0.14 | Why? |
| Brain Injuries, Traumatic | 1 | 2020 | 381 | 0.14 | Why? |
| Guinea-Bissau | 3 | 2018 | 22 | 0.14 | Why? |
| Radiology, Interventional | 1 | 2019 | 398 | 0.14 | Why? |
| Candida | 1 | 2019 | 425 | 0.14 | Why? |
| Receptors, Urokinase Plasminogen Activator | 1 | 2017 | 252 | 0.13 | Why? |
| Sick Leave | 1 | 2017 | 318 | 0.13 | Why? |
| Time Factors | 5 | 2020 | 31397 | 0.13 | Why? |
| Anemia, Sickle Cell | 1 | 2020 | 546 | 0.13 | Why? |
| CD8-Positive T-Lymphocytes | 3 | 2021 | 5837 | 0.13 | Why? |
| Genetic Variation | 2 | 2018 | 3919 | 0.13 | Why? |
| Sex Distribution | 1 | 2020 | 2083 | 0.13 | Why? |
| Practice Guidelines as Topic | 1 | 2017 | 15421 | 0.12 | Why? |
| Phantoms, Imaging | 1 | 2012 | 146 | 0.12 | Why? |
| Aortic Valve | 1 | 2019 | 664 | 0.12 | Why? |
| Transportation | 1 | 2018 | 691 | 0.12 | Why? |
| Risk Assessment | 4 | 2021 | 25439 | 0.12 | Why? |
| Brain Ischemia | 3 | 2018 | 2813 | 0.12 | Why? |
| Overweight | 1 | 2018 | 916 | 0.12 | Why? |
| Administration, Oral | 1 | 2019 | 2340 | 0.11 | Why? |
| Oligodeoxyribonucleotides | 1 | 2012 | 206 | 0.11 | Why? |
| DNA | 1 | 2017 | 778 | 0.11 | Why? |
| Cohort Studies | 6 | 2022 | 36005 | 0.11 | Why? |
| Weight Loss | 1 | 2017 | 826 | 0.11 | Why? |
| Return to Work | 1 | 2017 | 579 | 0.11 | Why? |
| Immunization, Secondary | 1 | 2019 | 1649 | 0.11 | Why? |
| Image Interpretation, Computer-Assisted | 1 | 2017 | 665 | 0.11 | Why? |
| Brain Neoplasms | 1 | 2017 | 669 | 0.10 | Why? |
| Alzheimer Disease | 1 | 2020 | 1020 | 0.10 | Why? |
| Neuroimaging | 1 | 2017 | 1106 | 0.10 | Why? |
| Hepatitis B | 1 | 2018 | 888 | 0.10 | Why? |
| Glycated Hemoglobin A | 1 | 2017 | 1316 | 0.09 | Why? |
| Drug Resistance, Bacterial | 1 | 2018 | 1414 | 0.09 | Why? |
| HIV Core Protein p24 | 2 | 2018 | 48 | 0.09 | Why? |
| Heart Failure | 2 | 2021 | 6638 | 0.09 | Why? |
| Gene Expression Profiling | 1 | 2019 | 3788 | 0.09 | Why? |
| Proviruses | 2 | 2018 | 82 | 0.09 | Why? |
| HIV Reverse Transcriptase | 2 | 2018 | 104 | 0.09 | Why? |
| Cause of Death | 2 | 2018 | 4823 | 0.09 | Why? |
| Hospitalization | 6 | 2021 | 54280 | 0.08 | Why? |
| Multivariate Analysis | 1 | 2018 | 5440 | 0.08 | Why? |
| Drug Combinations | 1 | 2017 | 3852 | 0.08 | Why? |
| Image Processing, Computer-Assisted | 2 | 2013 | 1383 | 0.08 | Why? |
| Comorbidity | 3 | 2021 | 34796 | 0.08 | Why? |
| Streptococcus pneumoniae | 1 | 2012 | 827 | 0.08 | Why? |
| Tuberculosis, Pulmonary | 1 | 2017 | 1171 | 0.08 | Why? |
| Aged, 80 and over | 7 | 2021 | 88759 | 0.08 | Why? |
| Pneumococcal Vaccines | 1 | 2012 | 571 | 0.08 | Why? |
| Cardiovascular Diseases | 2 | 2022 | 11497 | 0.08 | Why? |
| Anti-HIV Agents | 1 | 2018 | 2209 | 0.07 | Why? |
| Thrombolytic Therapy | 2 | 2018 | 2218 | 0.07 | Why? |
| Hypoxia | 1 | 2020 | 3626 | 0.07 | Why? |
| Pneumococcal Infections | 1 | 2012 | 562 | 0.07 | Why? |
| Echocardiography | 1 | 2019 | 3661 | 0.07 | Why? |
| Emergency Medical Services | 1 | 2021 | 3557 | 0.07 | Why? |
| Myocardial Infarction | 1 | 2021 | 3361 | 0.07 | Why? |
| Patient Safety | 1 | 2019 | 4885 | 0.07 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2020 | 3892 | 0.07 | Why? |
| Case-Control Studies | 2 | 2020 | 17671 | 0.06 | Why? |
| Retrospective Studies | 6 | 2021 | 105322 | 0.06 | Why? |
| Immunogenicity, Vaccine | 1 | 2018 | 4624 | 0.06 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 5277 | 0.06 | Why? |
| CD4 Lymphocyte Count | 2 | 2018 | 1517 | 0.06 | Why? |
| Sex Factors | 1 | 2019 | 11014 | 0.06 | Why? |
| RNA, Viral | 5 | 2021 | 32276 | 0.06 | Why? |
| Kidney Failure, Chronic | 1 | 2018 | 3222 | 0.06 | Why? |
| Animals | 3 | 2021 | 78931 | 0.06 | Why? |
| Double-Blind Method | 3 | 2020 | 5988 | 0.06 | Why? |
| Mutation | 2 | 2019 | 12376 | 0.06 | Why? |
| Adult | 17 | 2021 | 244371 | 0.06 | Why? |
| Clinical Protocols | 1 | 2013 | 2734 | 0.06 | Why? |
| Age Factors | 2 | 2019 | 21039 | 0.06 | Why? |
| Renal Dialysis | 1 | 2018 | 4358 | 0.05 | Why? |
| Prospective Studies | 4 | 2018 | 43301 | 0.05 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 13720 | 0.05 | Why? |
| Population Surveillance | 1 | 2017 | 4967 | 0.05 | Why? |
| Europe | 1 | 2017 | 12702 | 0.05 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.05 | Why? |
| Brain | 1 | 2017 | 5133 | 0.05 | Why? |
| Treatment Outcome | 4 | 2019 | 51732 | 0.05 | Why? |
| Adolescent | 6 | 2019 | 86841 | 0.05 | Why? |
| Intention to Treat Analysis | 1 | 2020 | 673 | 0.05 | Why? |
| Immunity, Innate | 1 | 2017 | 6570 | 0.05 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.05 | Why? |
| Sequence Analysis, DNA | 2 | 2018 | 2830 | 0.05 | Why? |
| Cryptococcus | 1 | 2018 | 29 | 0.05 | Why? |
| Prognosis | 2 | 2020 | 32490 | 0.05 | Why? |
| Infant | 2 | 2019 | 30274 | 0.04 | Why? |
| Administrative Personnel | 1 | 2021 | 326 | 0.04 | Why? |
| Vaccines, Combined | 1 | 2018 | 67 | 0.04 | Why? |
| Inflammation | 1 | 2021 | 13255 | 0.04 | Why? |
| Waist Circumference | 1 | 2018 | 199 | 0.04 | Why? |
| Myxovirus Resistance Proteins | 1 | 2017 | 77 | 0.04 | Why? |
| Hospital Mortality | 2 | 2018 | 22087 | 0.04 | Why? |
| Obesity | 1 | 2018 | 7388 | 0.04 | Why? |
| Prevalence | 1 | 2019 | 25773 | 0.04 | Why? |
| Child | 4 | 2021 | 70012 | 0.04 | Why? |
| Child, Preschool | 2 | 2019 | 36283 | 0.04 | Why? |
| Sustained Virologic Response | 1 | 2018 | 378 | 0.04 | Why? |
| Obesity, Abdominal | 1 | 2018 | 167 | 0.04 | Why? |
| Mycoplasma pneumoniae | 1 | 2018 | 233 | 0.04 | Why? |
| 2',5'-Oligoadenylate Synthetase | 1 | 2017 | 205 | 0.04 | Why? |
| Hepatitis B Surface Antigens | 1 | 2018 | 305 | 0.04 | Why? |
| Ubiquitins | 1 | 2017 | 202 | 0.04 | Why? |
| Blood-Brain Barrier | 1 | 2020 | 531 | 0.04 | Why? |
| Drug Therapy, Combination | 2 | 2020 | 7268 | 0.04 | Why? |
| Treatment Failure | 1 | 2020 | 2106 | 0.03 | Why? |
| Educational Status | 1 | 2021 | 1451 | 0.03 | Why? |
| Antibodies, Neutralizing | 1 | 2020 | 25288 | 0.03 | Why? |
| env Gene Products, Human Immunodeficiency Virus | 1 | 2017 | 386 | 0.03 | Why? |
| Vaccination | 1 | 2019 | 19050 | 0.03 | Why? |
| Morbidity | 1 | 2019 | 1426 | 0.03 | Why? |
| Adenosine Monophosphate | 2 | 2020 | 5652 | 0.03 | Why? |
| Alanine | 2 | 2020 | 5687 | 0.03 | Why? |
| Nasopharynx | 1 | 2012 | 10224 | 0.03 | Why? |
| Blood Volume | 1 | 2012 | 90 | 0.03 | Why? |
| Body Weight | 1 | 2018 | 1074 | 0.03 | Why? |
| Drug Prescriptions | 1 | 2020 | 1062 | 0.03 | Why? |
| Drug Resistance, Viral | 1 | 2018 | 1083 | 0.03 | Why? |
| Severity of Illness Index | 1 | 2019 | 48226 | 0.03 | Why? |
| Sample Size | 1 | 2013 | 518 | 0.03 | Why? |
| Radiography | 1 | 2018 | 1576 | 0.03 | Why? |
| Young Adult | 5 | 2019 | 93724 | 0.03 | Why? |
| Antitubercular Agents | 1 | 2017 | 775 | 0.03 | Why? |
| Microbial Sensitivity Tests | 1 | 2019 | 2886 | 0.03 | Why? |
| United States | 1 | 2017 | 46150 | 0.03 | Why? |
| Flow Cytometry | 1 | 2018 | 2393 | 0.02 | Why? |
| Analysis of Variance | 1 | 2012 | 950 | 0.02 | Why? |
| Cytokines | 3 | 2017 | 15010 | 0.02 | Why? |
| Combined Modality Therapy | 1 | 2018 | 3395 | 0.02 | Why? |
| Social Class | 1 | 2017 | 1360 | 0.02 | Why? |
| Interferon-alpha | 1 | 2017 | 1442 | 0.02 | Why? |
| Antigens, Bacterial | 1 | 2012 | 330 | 0.02 | Why? |
| Recurrence | 1 | 2019 | 3675 | 0.02 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 1261 | 0.02 | Why? |
| Dendritic Cells | 1 | 2017 | 1330 | 0.02 | Why? |
| Antifungal Agents | 1 | 2019 | 1828 | 0.02 | Why? |
| Antihypertensive Agents | 1 | 2020 | 1962 | 0.02 | Why? |
| Interferon-gamma | 1 | 2018 | 2711 | 0.02 | Why? |
| DNA, Viral | 1 | 2018 | 2521 | 0.02 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.02 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.02 | Why? |
| Lymphocyte Activation | 1 | 2017 | 2742 | 0.02 | Why? |
| Viral Load | 2 | 2018 | 15850 | 0.02 | Why? |
| Anesthesia | 1 | 2017 | 1236 | 0.02 | Why? |
| Killer Cells, Natural | 1 | 2017 | 2093 | 0.02 | Why? |
| Tissue Plasminogen Activator | 1 | 2013 | 778 | 0.02 | Why? |
| Odds Ratio | 1 | 2018 | 5861 | 0.02 | Why? |
| Genotype | 1 | 2018 | 4697 | 0.02 | Why? |
| Tomography, X-Ray Computed | 1 | 2012 | 25144 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2021 | 10017 | 0.02 | Why? |
| Drug Administration Schedule | 1 | 2012 | 2324 | 0.02 | Why? |
| Delivery of Health Care | 2 | 2021 | 15909 | 0.02 | Why? |
| Glucocorticoids | 1 | 2020 | 4431 | 0.02 | Why? |
| Immunity, Cellular | 1 | 2017 | 3614 | 0.02 | Why? |
| Immunotherapy | 1 | 2017 | 2421 | 0.02 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2018 | 9893 | 0.02 | Why? |
| Recombinant Proteins | 1 | 2013 | 3786 | 0.01 | Why? |
| Hospitals | 1 | 2021 | 11793 | 0.01 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.01 | Why? |
| Communicable Disease Control | 2 | 2022 | 29620 | 0.01 | Why? |
| Fibrinolytic Agents | 1 | 2013 | 1702 | 0.01 | Why? |
| Mice, Inbred BALB C | 1 | 2012 | 5814 | 0.01 | Why? |
| Health Personnel | 2 | 2021 | 29646 | 0.01 | Why? |
| Disease Management | 1 | 2019 | 6841 | 0.01 | Why? |
| Software | 1 | 2012 | 2501 | 0.01 | Why? |
| T-Lymphocytes | 1 | 2018 | 6670 | 0.01 | Why? |
| Sleep | 1 | 2013 | 2695 | 0.01 | Why? |
| Health Behavior | 1 | 2018 | 4449 | 0.01 | Why? |
| Phylogeny | 1 | 2018 | 13341 | 0.01 | Why? |
| Gene Expression Regulation | 1 | 2012 | 4020 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2018 | 7330 | 0.01 | Why? |
| Hypertension | 1 | 2020 | 8895 | 0.01 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 9706 | 0.01 | Why? |
| Patient Selection | 1 | 2013 | 4560 | 0.01 | Why? |
| Infant, Newborn | 1 | 2019 | 23105 | 0.01 | Why? |
| Pregnancy | 1 | 2018 | 23879 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2012 | 11304 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2017 | 22971 | 0.01 | Why? |
| Algorithms | 1 | 2012 | 7346 | 0.01 | Why? |
| Biomarkers | 1 | 2017 | 23361 | 0.01 | Why? |
| Mice | 1 | 2012 | 21357 | 0.01 | Why? |
| Antibodies, Viral | 1 | 2021 | 51949 | 0.01 | Why? |